Imidazopyridone compound combined with sigma-2 receptor as well as preparation method and application of imidazopyridone compound

By developing imidazolopyridone compounds of σ2 receptor/TMEM97, the problem of insufficient affinity and specificity of existing probes was solved, and efficient tumor and atherosclerotic plaque imaging was achieved, with excellent biological academic nature and clinical application prospects.

CN118994151AActive Publication Date: 2024-11-22BEIJING NORMAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411093126.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-22
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The existing σ2 receptor/TMEM97 molecular probes are insufficient in tumor imaging, and have poor selectivity for the subtype of σ1 receptor, resulting in tissue non-target uptake interfering with the judgment of tumor positive signals.

Method used

Develop an imidazolopyridone compound that binds σ2 receptor/TMEM97 to prepare 18F labeled compounds with nanomolar order of magnitude affinity, high subtype selectivity and specificity for PET imaging by specific synthetic pathways .

Benefits of technology

It has achieved efficient visualization of tumor proliferation status and atherosclerotic plaque imaging, with high radiochemical yield and purity, excellent biological properties, and is suitable for clinical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994151A_ABST
    Figure CN118994151A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of radiopharmaceutical chemistry and clinical nuclear medicine, and particularly relates to a preparation method and application of an imidazopyridone compound combined with a sigma-2 (sigma 2) receptor. The structural general formula of the compound is as shown in formula (I), and the compound has nanomole order of magnitude affinity, high subtype selectivity and specificity for a sigma2 receptor / TMEM97. When the R group in the compound of the formula (I) is 18F, the corresponding tracer agent is prepared by carrying out nucleophilic substitution on the-OTs substituted labeled precursor through 18F, and the tracer agent has high radiochemical yield and radiochemical purity, has excellent biological properties, can be applied to PET imaging of tumor proliferation states and atherosclerotic plaques, and has wide clinical application prospects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of radiopharmaceutical chemistry and clinical nuclear medicine technology, and in particular to an imidazopyridone compound binding to a sigma-2 (σ2) receptor, and a preparation method and application thereof. Background Art

[0002] Sigma (σ) receptors are a new type of receptor that is different from opioid receptors, including two subtypes, sigma-1 (σ1) and sigma-2 (σ2). In 2017, the σ2 receptor was identified as transmembrane protein 97 (TMEM97) located in the endoplasmic reticulum. σ2 receptor / TMEM97 is a regulatory gene for lipid and cholesterol metabolism. Its expression in tumor proliferative cells is 8-10 times that in the resting period and is a biomarker for tumor proliferation. Therefore, σ2 receptor / TMEM97 is a target related to lipid and cholesterol metabolism that reflects the proliferation state of tumor cells. Positron emission tomography (PET imaging) targeting σ2 receptor / TMEM97 helps to achieve early diagnosis of cancer, assist clinical treatment planning, and evaluate patient treatment efficacy and prognosis.

[0003] Colorectal cancer (CRC) is the most common digestive system malignancy, with an incidence of 10.2% of all cancers, and is the second most common cause of cancer death. The spread of the disease to distant organs is considered to be the main cause of death in CRC patients. About 20% of CRC patients are found to have metastatic lesions at the time of diagnosis, of which pulmonary metastases account for 10% to 15%, making it the second most common site of CRC metastasis, second only to the liver, and also the most common site of extraperitoneal metastasis. Lung metastasis often indicates that the patient's condition has reached an advanced stage, with a poor prognosis and a short overall survival. For patients with tumors that have lung metastases, timely and effective delay and termination of the metastatic process will significantly improve the patient's survival.

[0004] Although drug treatment for tumors has developed rapidly in recent years, surgical treatment is currently the only way for patients with colorectal cancer to achieve long-term survival. The treatment strategies for patients with metastatic colorectal cancer are completely different from those for patients with non-metastatic colorectal cancer. The surgical indications for patients with colorectal cancer with distant metastases should be strictly controlled, especially when the metastatic lesions are in a period of rapid proliferation. After COVID-19, the detection rate of lung nodules has increased significantly compared with before. For patients with colorectal cancer, determining whether their lung nodules are tumor metastases and the proliferation of these metastatic lesions play a decisive role in the patient's treatment strategy. Although pathological diagnosis is the gold standard for determining lung metastasis, it is somewhat traumatic. At the same time, there is a high risk of sampling metastatic lesions around the heart. [ 18F]FDG imaging is currently the most widely used non-invasive method for determining lung metastasis in clinical practice. However, due to the high uptake of contrast agents by the heart, the heart has a certain "masking" effect on the lesions around it, and the glucose uptake capacity cannot fully represent the proliferation activity of the tumor. Given that σ2 receptor / TMEM97 is a biomarker that regulates cholesterol homeostasis and reflects the state of tumor proliferation, the use of σ2 receptor / TMEM97 tumor imaging agents for in vivo imaging of colorectal cancer patients is helpful to distinguish between patients with metastatic colorectal cancer and non-metastatic colorectal cancer, determine whether the lung nodules of colorectal cancer patients are tumor metastasis and the proliferation of these metastatic lesions, and determine the patient's treatment strategy. Therefore, the design and development of σ2 receptor / TMEM97 tumor imaging agents will provide an efficient tool for visualizing the state of tumor proliferation.

[0005] σ2 receptor / TMEM97 has been very active in the field of tumor research. Its radionuclides (especially 99m Tc and 18 F) labeled σ2 receptor ligands are often used in tumor imaging research. Although there are many reports of σ2 receptor radioligands used in tumor imaging, such as PET imaging agents [ 11 C]RHM-1, 18 F]ISO-1 and [ 18 F]RHM-4, and SPECT imaging agents [ 123 I]RHM-4. However, currently only PET imaging agents [ 18 F]ISO-1 has entered Phase I clinical trials for multiple tumor studies (such as breast cancer, lymphoma, and head and neck cancer). 18 F]ISO-1 has entered human trials, but the probe still has some shortcomings, such as low affinity and specificity for σ2 receptor / TMEM97, poor subtype selectivity for σ1 receptor, and relatively high lipid solubility (logD 7.4 =3.06), resulting in higher non-target tissue uptake, which interferes with the judgment of tumor positive signals.

[0006] Studies have shown that the deposition and oxidation of low-density lipoprotein (LDL) in the arterial wall is one of the initiating factors of plaque formation. σ2 receptor / TMEM97 is a cholesterol regulatory gene. σ2 receptor / TMEM97, progesterone receptor membrane component 1 (PGRMC1) and low-density lipoprotein receptor (LDLR) form a ternary complex that mediates the absorption of low-density lipoprotein. Therefore, σ2 receptor / TMEM97 is an ideal target for identifying rapidly progressing vulnerable plaques. Using the obtained molecular probes with excellent properties, the expression level of σ2 receptor / TMEM97 during plaque formation and progression was quantitatively visualized in vivo, and the temporal and spatial changes of σ2 receptor / TMEM97 expression in atherosclerotic plaque models were deeply explored, as well as the key role of σ2 receptor / TMEM97 in plaque formation and development.

[0007] Therefore, the development of high-affinity and high-selectivity σ2 receptor / TMEM97 molecular probes can provide sensitive tools for visualizing tumor proliferation status and imaging atherosclerotic plaques.

[0008] Radionuclides 18 F has a suitable half-life (T 1 / 2 =109.8min), easy preparation, can be used for non-invasive PET imaging, and data can be quantitatively analyzed. Therefore, the research has suitable affinity, high selectivity, and excellent metabolic properties in the body. 18 The F-labeled specific σ2 receptor / TMEM97 PET imaging agent has important clinical application prospects for the visualization study of tumor proliferation status. Summary of the invention

[0009] In view of the problems existing in the existing σ2 receptor / TMEM97 molecular probes, the present invention provides an imidazopyridone compound that can bind to σ2 receptor / TMEM97, and a preparation method and application thereof. The compound has nanomolar affinity, high subtype selectivity and specificity for σ2 receptor / TMEM97, can be applied to PET imaging of tumor proliferation status, and has broad clinical application prospects.

[0010] In the first aspect, the imidazopyridone compound capable of binding to σ2 receptor / TMEM97 of the present invention has a structure shown in the general formula (I):

[0011]

[0012] Where:

[0013] R is F or 18 F.

[0014] Preferably, when R is 18F, the compound can be used for imaging.

[0015] In a second aspect, the present invention further provides a method for preparing the above compound.

[0016] When R in the general formula (I) is F or 18 When F, the corresponding compound is prepared by the following synthetic route:

[0017]

[0018] The preparation steps corresponding to the above synthetic route are as follows:

[0019] (a) In tetrahydrofuran solvent, compound 1 (2-amino-3-nitro-6-methoxypyridine) reacts with di-tert-butyl dicarbonate under the action of 4-dimethylaminopyridine, followed by the addition of potassium carbonate and methanol to obtain compound 2; the reaction temperature is 55-65°C;

[0020] (b) In methanol solvent, compound 2 reacts with 10% palladium on carbon under a hydrogen atmosphere to obtain compound 3; the reaction temperature is 50°C;

[0021] (c) In tetrahydrofuran solvent, compound 3 reacts with N,N'-carbonyldiimidazole in the presence of triethylamine to obtain compound 4;

[0022] (d) In a solvent of N,N-dimethylformamide, compound 4 reacts with 1,4-dibromobutane in the presence of potassium carbonate and tetrabutylammonium iodide to obtain compound 5; the reaction temperature is 60°C;

[0023] (e) In acetonitrile as a solvent, compound 5 reacts with 5,6-dimethoxyisoindoline in the presence of potassium carbonate and triethylamine to obtain compound 6;

[0024] (f) Compound 6 reacts with trifluoroacetic acid in a solvent of dichloromethane at room temperature to obtain compound 7;

[0025] (g) In a solvent of N,N-dimethylformamide, compound 7 reacts with 1-bromo-2-fluoroethane in the presence of potassium carbonate and tetrabutylammonium iodide to obtain compound 8; the reaction temperature is 65° C.;

[0026] (h) In a solvent of N,N-dimethylformamide, compound 7 reacts with (2-bromoethoxy)-tert-butyldimethylsilane in the presence of potassium carbonate and tetrabutylammonium iodide to obtain compound 9; the reaction temperature is 60° C.;

[0027] (i) Compound 9 reacts with 4 mol / L methanolic hydrochloric acid at room temperature in methanol solvent to obtain compound 10;

[0028] (j) In a solvent of dichloromethane, compound 10 reacts with p-toluenesulfonyl chloride in the presence of triethylamine and 4-dimethylaminopyridine at room temperature to obtain compound 11; p-toluenesulfonyl chloride is added at 0°C;

[0029] (k) Under sealed conditions, compound 11 and 4,7,13,16,21,24-hexaoxo-1,10-diazabicyclo[8.8.8]hexacosane (K 2.2.2 ) reacts under the action of potassium carbonate to obtain 18 F-labeled imidazopyridone σ2 receptor / TMEM97 compounds [ 18 F]8.

[0030] The specific conditions of the above steps are as follows:

[0031] The reaction reagents and conditions of each step are as follows:

[0032] (a) di-tert-butyl dicarbonate, 4-dimethylaminopyridine, tetrahydrofuran, react at 65°C for 1 hour; after cooling, add potassium carbonate and methanol, and react at 55°C for 2 hours;

[0033] (b) 10% palladium carbon, hydrogen, methanol, 50°C, reaction for 12 hours;

[0034] (c) N,N'-carbonyldiimidazole, triethylamine, tetrahydrofuran, 50°C for 2 hours;

[0035] (d) 1,4-dibromobutane, potassium carbonate, tetrabutylammonium iodide, N,N-dimethylformamide, reaction at 60°C for 2 hours;

[0036] (e) 5,6-dimethoxyisoindoline, potassium carbonate, triethylamine, acetonitrile, heated to reflux for 12 hours;

[0037] (f) Trifluoroacetic acid, dichloromethane, react at room temperature for 12 hours;

[0038] (g) 1-bromo-2-fluoroethane, potassium carbonate, tetrabutylammonium iodide, N,N-dimethylformamide, reaction at 65°C for 12 hours;

[0039] (h) (2-bromoethoxy)-tert-butyldimethylsilane, potassium carbonate, tetrabutylammonium iodide, N,N-dimethylformamide, reaction at 60°C for 2 hours;

[0040] (i) 4 mol / L hydrochloric acid methanol, methanol, react at room temperature for 30 minutes;

[0041] (j) p-Toluenesulfonyl chloride, triethylamine, 4-dimethylaminopyridine, and dichloromethane were added at 0°C and reacted at room temperature for 12 hours;

[0042] (k) 4,7,13,16,21,24-hexaoxo-1,10-diazabicyclo[8.8.8]hexacosane (K 2.2.2 ), potassium carbonate, acetonitrile, 100°C, reaction for 8 minutes.

[0043] As one of the specific embodiments, when R in the general formula (I) is 18 F, the above step (k) specifically includes the following steps:

[0044] S1. Activate the QMA column with 10 mL of NaHCO3 (10%), 10 mL of H2O, and 10 mL of ethanol, respectively, to capture fluoride ions.

[0045] S2. Prepare 1 mL K 2.2.2 / K2CO3 eluent will [ 18 F]F - Elute from the QMA column into a reaction flask, heat at 110°C under N2 to remove water, and then dry with anhydrous acetonitrile three times.

[0046] S3. After the water removal is completed, seal the reaction bottle, dissolve about 2 mg of the labeled precursor in 0.5 mL of anhydrous CH3CN, and transfer it to the reaction bottle containing [ 18 F]F - / K 2.2.2 The complex is fully mixed in a reaction bottle and heated at 100° C. for 8 min to obtain.

[0047] Among them, as described in S2 [ 18 F]F - / K 2.2.2 The complex is K containing 13 mg of 4,7,13,16,21,24-hexaoxo-1,10-diazabicyclo[8.8.8]hexacosane and 1.1 mg of potassium carbonate. + [ 18 F]F - Mixture, radioactivity 10-1000mCi.

[0048] In this scheme, the reaction product is separated and purified by HPLC. Preferably, the HPLC conditions are as follows: the mobile phase of the HPLC semi-preparative column (ReproSil-Pur Basic-C18 column, 250 mm×10 mm, 5 μm) is preferably 50% acetonitrile aqueous solution containing 0.1% triethylamine, and the flow rate is 4 mL / min.

[0049] In this scheme, the obtained reaction product is identified by HPLC. Preferably, the HPLC conditions are as follows: analytical column (Agela Venusil MP C18 column, 250 mm×4.6 mm, 5 μm), HPLC analysis mobile phase is preferably 50% acetonitrile aqueous solution containing 0.1% triethylamine, and the flow rate is 1 mL / min.

[0050] Under the above conditions, a product with a radiochemical purity greater than 99% can be obtained.

[0051] In a third aspect, the present invention further provides a ligand targeting σ2 receptor / TMEM97, which contains the compound represented by the above general formula (I).

[0052] In a fourth aspect, the present invention also provides a molecular probe for binding to σ2 receptor / TMEM97, comprising the general formula (I) wherein R is 18 F is the corresponding compound.

[0053] In a fifth aspect, the present invention further provides a tumor imaging agent targeting σ2 receptor / TMEM97, comprising the general formula (I) wherein R is 18 F is the corresponding compound.

[0054] In a sixth aspect, the present invention further provides the use of the above-mentioned molecular probes for binding to σ2 receptor / TMEM97, tumor imaging agents targeting σ2 receptor / TMEM97 in positron emission tomography imaging agents, or in the preparation of products for diagnosis, staging or efficacy evaluation of cancer patients.

[0055] The beneficial effects of the present invention are as follows:

[0056] The imidazopyridone σ2 receptor / TMEM97 compound provided by the present invention has nanomolar affinity, high subtype selectivity and specificity for σ2 receptor / TMEM97. When the R group in the compound of formula (I) is 18 F, after 18 F performs nucleophilic substitution on -OTs-substituted labeled precursors to prepare the corresponding tracers, which have high radiochemical yield and radiochemical purity, excellent biological properties, can be applied to PET imaging of tumor proliferation status, and have broad clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 In Example 11 of the present invention 18 F-labeled compounds [ 18 F] HPLC analysis of 8 after incubation in normal saline for 30min, 60min, and 120min.

[0058] Figure 2 The inhibitor CM398 is used to treat the 18 F-labeled compounds [ 18 F]8 uptake inhibition results in the brain and peripheral organs of normal mice.

[0059] Figure 3 In Example 11 of the present invention 18 F-labeled compounds [ 18 F]8 P-gp substrate experiment in normal mice.

[0060] Figure 4 In Example 11 of the present invention 18 F-labeled compounds [ 18 HPLC analysis of radioactive metabolites of F8 in nude mice bearing CT26 tumors.

[0061] Figure 5 In Example 11 of the present invention 18 F-labeled compounds [ 18 F]8 Results of micro-PET / CT imaging and CM398 inhibition experiments in nude mice bearing CT26 tumors. In the figure, A, E and C, G are the imaging results at 30 min and 90 min, respectively; B, F and D, H are the imaging inhibition results at 30 min and 90 min, respectively (A, B, C, D are sagittal planes, E, F, G, H are coronal planes).

[0062] Figure 6 In Example 11 of the present invention 18 F-labeled compounds [ 18 F]8 and [ 18 Comparison of micro-PET / CT imaging results of F]FDG in CT26 lung compression model mice. Figure A and C are [ 18 F]FDG imaging results, B and D are [ 18 F]8 Imaging results (A and B are sagittal planes, C and D are coronal planes).

[0063] Figure 7 The isolated aorta oil red of atherosclerosis model mice and normal C57 mice and the 18 F-labeled compounds [ 18 F]8 In vitro autoradiography comparison (the pink arrow indicates the plaque site)

[0064] Figure 8 In Example 11 of the present invention 18 F-labeled compounds [ 18 F]8 60 min in vivo + thymus removal imaging in normal C57 mice and atherosclerosis model mice. The yellow circle is the thymus site and the pink circle is the aortic arch site. DETAILED DESCRIPTION

[0065] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0066] The synthetic routes of the compounds of Examples 1-10 of the present invention and the radioactive nuclide fluorine-18 labeling route of Example 11 are as follows:

[0067]

[0068] The "%" mentioned in the present invention regarding the solution concentration all represents the volume percentage concentration, and the calculation formula is: volume percentage concentration of the solution = solute volume / solution volume × 100%.

[0069] Example 1 Synthesis of Intermediate 2

[0070] Compound 1 (1.2 g, 10 mmol) was dissolved in 20 mL of tetrahydrofuran, and (Boc)2O (6.5 g, 30 mmol) and 4-dimethylaminopyridine (DMAP, 122 mg, 1 mmol) were added in sequence. The mixture was heated to reflux at 65 °C for 1 h. After cooling to room temperature, K2CO3 (4.1 g, 30 mmol) was added, and 50 mL of methanol was added. The mixture was heated to reflux at 55 °C for 2 h. After cooling to room temperature, the solvent was removed by rotary evaporation. 50 mL of water was added to the reaction flask, and the mixture was extracted with dichloromethane (3×50 mL). The organic phase was washed with saturated brine, and then the organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (PE:EA=6:1) to obtain intermediate 2, the structure of which is as follows. The yield was 38.6%, light green crystals, and the developing system PE:EA=3:1 (R f =0.5). 1 H NMR (600MHz, DMSO-d6): δ10.19(s,1H),8.27(d,J=8.9Hz,1H),6.65(d,J=8.9Hz,1H),3.89(s,3H),1.39(s,9H).ESI-MS calcd.for C 11 H 15 N3NaO5[M+Na] + m / z 292.10; found m / z 292.09.

[0071]

[0072] Example 2 Synthesis of Intermediate 3

[0073] Dissolve intermediate 2 (1.7 g, 4.5 mmol) in 10 mL methanol, add 10% Pd / C (46 mg, 0.45 mmol), introduce H2, reflux overnight at 50°C, cool to room temperature, filter under reduced pressure, remove solvent by rotary evaporation, dissolve the crude product in methanol and dry column, separate and purify by silica gel column chromatography (PE: EA = 3: 1) to obtain intermediate 3, the structure of which is as follows. Yield 92.4%, light pink powder, developing system PE: EA = 4: 1 (R f =0.3). 1 H NMR (600MHz, DMSO-d6): δ8.83(s,1H),7.11(d,J=8.4Hz,1H),6.42(d,J=8.4Hz,1H),4.39(s,2H),3.66(s,3H),1.41(s,9H).ESI-MScalcd.for C 11 H 18 N3O3[M+H] + m / z 240.13; found m / z 240.13.

[0074]

[0075] Example 3 Synthesis of Intermediate 4

[0076] Dissolve intermediate 3 (500 mg, 2.1 mmol) in 10 mL tetrahydrofuran, add N, N'-carbonyldiimidazole (CDI, 374 mg, 2.3 mmol), triethylamine (TEA, 608 μL, 4.2 mmol), introduce N2, heat under reflux at 50 ° C for 5 h, cool to room temperature, and remove the solvent by rotary evaporation. Dissolve the crude product in dichloromethane and methanol and dry-load it on the column. Separate and purify it by silica gel column chromatography (PE: EA = 7: 3) to obtain intermediate 4, the structure of which is as follows. Yield 36.4%, white solid, development system PE: EA = 3: 1 (R f =0.4). 1 H NMR (400MHz, DMSO-d6): δ11.80(s,1H),7.75(d,J=8.6Hz,1H),6.45(d,J=8.6Hz,1H),3.77(s,3H),1.53(s,9H).ESI-MS calcd for C 12 H 16 N3O4[M+H] + m / z 266.11; found m / z 266.11.

[0077]

[0078] Example 4 Synthesis of Intermediate 5

[0079] Dissolve intermediate 4 in 5 mL DMF, add K2CO3 (1 g, 7.5 mmol), TBAI (139 mg, 0.4 mmol), 1,4-dibromobutane (271 μL, 2.3 mmol) in sequence, heat under reflux at 65 ° C for 2 h, add 50 mL of water to the reaction bottle to quench, and extract with dichloromethane (3×50 mL). The organic phase was washed with saturated brine, then combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (PE: EA = 3: 1) to obtain intermediate 5, the structure of which is as follows. Yield 34.2%, yellow oily liquid, developing system PE: EA = 3: 1 (R f =0.7). 1 H NMR (600MHz, DMSO-d6): δ7.80(d,J=8.5Hz,1H), 6.50(d,J=8.5Hz,1H), 3.83(s,3H), 3.80(t,J=6.2Hz,2H),3.55(t,J=6.1Hz,2H),1.85–1.74(m,4H),1.54(s,9H).ESI-MS calcd.for C 16 H 23 BrN3O4[M+H] + m / z 400.09; found m / z 400.09.

[0080]

[0081] Example 5 Synthesis of Intermediate 6

[0082] The intermediate 5 (380 mg, 0.9 mmol) was dissolved in 5 mL of acetonitrile, and K2CO3 (262 mg, 1.9 mmol), triethylamine (TEA, 138 μL, 0.9 mmol) and 5,6-dimethoxyisoindole (187 mg, 1 mmol) were added in sequence. The mixture was heated to reflux overnight at 90 °C, cooled to room temperature, and the solvent was removed by rotary evaporation. 20 mL of water was added to the reaction flask to quench the mixture, and the mixture was extracted with dichloromethane (3×20 mL). The organic phase was washed with saturated brine, and then the organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (PE: EA: MeOH: TEA = 10: 25: 1: 0.5) to obtain the intermediate 6, the structure of which is as follows. The yield was 37.3%, brown oily liquid, and the developing system was PE: EA: MeOH: TEA = 10: 25: 1: 1 (R f =0.5). 1H NMR (600MHz, Chloroform-d): δ7.86 (d, J=8.5Hz, 1H), 6.71 (s, 2H), 6.43 (d, J=8.5Hz, 1H), 3.96 (q, J=7 .5Hz,3H),3.90(d,J=10.9Hz,6H),3.84(s,6H),2.79(s,2H),1.93–1.88(m,2H),1.65(s,11H).ESI-MS calcd.for C 26 H 35 N4O6[M+H] + m / z 499.25; found m / z 499.25.

[0083]

[0084] Example 6 Synthesis of Intermediate 7

[0085] Dissolve intermediate 6 (176 mg, 0.35 mmol) in 5 mL of dichloromethane, add 1 mL of trifluoroacetic acid, and stir at room temperature for 1 h. Add 20 mL of water to the reaction flask to quench, add saturated NaHCO3 solution until the pH is 9-10, and extract with dichloromethane (3×20 mL). The organic phase is washed with saturated brine, then the organic phases are combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product is separated and purified by silica gel column chromatography (PE: EA: MeOH: TEA = 10: 25: 1: 0.5) to obtain intermediate 7, the structure of which is as follows. Yield 78.2%, white solid, development system PE: EA: MeOH: TEA = 10: 25: 1: 1 (R f =0.2). 1 H NMR (400MHz, DMSO-d6): δ10.77(s,1H),7.24(d,J=8.2Hz,1H),6.78(d,J=4.0Hz,2H),6.36(d,J=8.3Hz,1H),3.77(d ,J=3.7Hz,5H),3.67(d,J=7.6Hz,10H),2.63(t,J=6.9Hz,2H),1.76(t,J=7.1Hz,2H),1.44(t,J=7.4Hz,2H).ESI-MS calcd.for C 21 H 27 N4O4[M+H] + m / z 399.20; found m / z 399.20.

[0086]

[0087] Example 7 Synthesis of Standard Product 8

[0088] The intermediate 7 (51 mg, 0.14 mmol) was dissolved in DMF (5 mL), and K2CO3 (58 mg, 0.42 mmol), phase transfer catalyst TBAI (10 mg, 0.03 mmol) and 1-bromo-2-fluoroethane (44 mg, 0.35 mmol) were added in sequence, and the reaction was carried out at 60 ° C for 2 h. 20 mL of water was added to the reaction bottle to quench, and extracted with dichloromethane (3×20 mL). The organic phase was washed with saturated brine, and then the organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (PE: EA: MeOH: TEA = 10: 20: 1: 0.5) to obtain standard product 8, the structure of which is as follows. Yield 39%, white solid, development system PE: EA: MeOH: TEA = 10: 20: 1: 1 (R f =0.2). 1 H NMR (600MHz, Chloroform-d): δ7.25–7.22(m,1H),6.72(s,2H),6.42(d,J=8.4Hz,1H),4.69(dt,J=47.1,4.7Hz,2H),4.14(dt, J=27.4,4.7Hz,2H),4.00(t,J=7.1Hz,2H),3.91(s,7H),3.84(s,6H),2.85–2.73(m,2H),1.99–1.90(m,2H),1.70–1.64(m,2H). 13 C NMR (150MHz, Chloroform-d): δ160.10,153.66,148.48,141.05,131.66,118.29,117.78,105.96,10 1.37,82.78(d,J=170.7Hz),59.25,56.21,55.62,54.02,41.86(d,J=20.9Hz),40.00,26.30,26.14. 19 F NMR(565MHz,Chloroform-d):δ-219.90–-220.24(m).HR-MS calcd.for C 23 H 30 FN4O4[M+H] + m / z445.2245; found m / z 445.2248.

[0089]

[0090] Example 8 Synthesis of Intermediate 9

[0091] The intermediate 7 (50 mg, 0.125 mmol) was dissolved in DMF (5 mL), and K2CO3 (69 mg, 0.5 mmol), phase transfer catalyst TBAI (23 mg, 0.06 mmol) and (2-bromoethoxy)-tert-butyldimethylsilane (83 μL, 0.375 mmol) were added in sequence. The mixture was heated to reflux at 60 °C for 2 h, cooled to room temperature, and the solvent was removed by rotary evaporation. 20 mL of water was added to the reaction flask and extracted with dichloromethane (3×20 mL). The organic phase was washed with saturated brine, then the organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (PE: EA: MeOH: TEA = 10: 20: 1: 1) to obtain the intermediate 9, the structure of which is as follows. The yield was 84.8%, green oily liquid, and the developing system was PE: EA: MeOH: TEA = 10: 20: 1: 1 (R f =0.5). 1 H NMR (600MHz, Chloroform-d): δ7.25 (s, 1H), 6.71 (s, 2H), 6.39 (d, J = 8.3Hz, 1H), 3.99 (t, J = 7.1Hz, 2H), 3.94 (t, J = 5.3Hz, 2H), 3.91–3.85(m,9H),3.84(s,6H),2.78(s,2H),1.92(p,J=7.3Hz,2H),1.65(d,J=7.2Hz,2H),0.78(s,9H),-0.10(s,6H).ESI-MS calcd.forC 29 H 45 N4O5Si[M+H] + m / z 557.31; found m / z 557.31.

[0092]

[0093] Example 9 Synthesis of Intermediate 10

[0094] Dissolve intermediate 9 (50 mg, 0.09 mmol) in 5 mL of methanol, add 1 mL of methanolic hydrochloric acid solution, react for 30 min at room temperature, remove the solvent by rotary evaporation, add 20 mL of water to the reaction bottle to quench, add saturated NaHCO3 solution dropwise to pH 9-10, and extract with dichloromethane (3×20 mL). Concentrate under reduced pressure to obtain intermediate 10, the structure of which is as follows. The crude product is a yellow solid, and the developing system is PE:EA:MeOH:TEA=10:20:1:1 (R f =0.2). 1H NMR (600MHz, DMSO-d6): δ7.48(d,J=8.3Hz,1H),6.86(s,2H),6.44(d,J=8.3Hz,1H),4.82(d,J=5.8Hz,1H),3.88–3 .71(m,9H),3.68(s,6H),3.59(q,J=5.4Hz,2H),3.03(d,J=7.5Hz,4H),1.78(p,J=7.0Hz,2H),1.56(s,2H).ESI-MS calcd.for C 23 H 31 N4O5[M+H] + m / z 443.22; found m / z 443.23.

[0095]

[0096] Example 10 Synthesis of Labeled Precursor 11

[0097] Under ice bath conditions, the intermediate 9 (40 mg, 0.09 mmol) was dissolved in 5 mL of dichloromethane, and triethylamine (13 μL, 0.09 mmol), DMAP (2 mg, 0.018 mmol) and TsCl (34 mg, 0.18 mmol) were added in sequence, and the reaction was carried out at room temperature for 2 h. 20 mL of water was added to the reaction flask and extracted with dichloromethane (3×20 mL). The organic phase was washed with saturated brine, and then the organic phases were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (PE: EA: MeOH: TEA = 10: 20: 1.5: 1) to obtain the labeled precursor 10, the structure of which is as follows. The yield was 53.7%, yellow solid, and the development system was PE: EA: MeOH: TEA = 10: 20: 2: 1 (R f =0.4). 1 H NMR (400MHz, Chloroform-d): δ7.55(d,J=8.1Hz,2H),7.18(t,J=7.7Hz,3H),6.71(s,2H),6.40(d,J=8.3Hz,1H),4.30(t,J=5.0Hz,2H) ,4.07(t,J=5.1Hz,2H),3.96–3.85(m,9H),3.83(s,6H),2.78(t,J=7.5Hz,2H),2.38(s,3H),1.87(p,J=7.4Hz,2H),1.69–1.55(m,2H). 13C NMR(101MHz,Chloroform-d)δ160.05,153.33,148.54,145.07,140.77,132.39,129.78,127.74,118 .18,117.43,105.89,101.45,68.31,59.22,56.20,55.56,54.04,40.59,39.81,26.23,21.73.HR-MS calcd.for C 30 H 37 N4O7S[M+H] + m / z597.2377; found m / z 597.2381.

[0098]

[0099] Embodiment 11 18 F-labeled imidazopyridone σ2 receptor / TMEM97 compounds [ 18 The preparation of F]8 comprises the following steps:

[0100] (1) A QMA column was activated with NaHCO3 (10%, 10 mL), H2O (10 mL), and ethanol (10 mL) for capturing fluoride ions. A C-18 column was activated with ethanol (10 mL) and H2O for solid phase extraction.

[0101] (2) Use the prepared K 2.2.2 / K2CO3 eluent (1 mL) 18 F]F - Elute from the QMA column into a reaction flask, heat at 110°C under N2 to remove water, and then dry with anhydrous acetonitrile three times.

[0102] (3) After the water removal is completed, the reaction bottle is sealed, and about 2 mg of the labeled precursor (Compound 11) is dissolved in 0.5 mL of anhydrous CH3CN and transferred to the reaction bottle containing [ 18 F]F- / K 2.2.2 The complex is fully mixed in a reaction bottle and heated at 100° C. for 8 min to obtain.

[0103] Among them, (3) 18 F]F - / K 2.2.2 The complex contains 13 mg of 4,7,13,16,21,24-hexaoxo-1,10-diazabicyclo[8.8.8]hexacosane (K 2.2.2 ) and 1.1 mg potassium carbonate + [ 18 F]F -Mixture, radioactivity 10-1000mCi.

[0104] (4) After the reaction is completed, the mixture is cooled to room temperature, the radioactivity is measured, and the product is separated and purified by HPLC. In this scheme, preferably, the HPLC conditions are as follows: the mobile phase of the HPLC semi-preparative column (ReproSil-Pur Basic-C18 column, 250×10 mm, 5 μm) is preferably 50% acetonitrile aqueous solution containing 0.1% triethylamine, and the flow rate is 4 mL / min.

[0105] (5) Product identification after separation and purification: In this scheme, the obtained reaction product is identified by HPLC. As a preferred embodiment, the HPLC conditions are as follows: an analytical column (Agela Venusil MP C18 column, 250×4.6 mm, 5 μm), and the HPLC analysis mobile phase is preferably a 50% acetonitrile aqueous solution containing 0.1% triethylamine, and the flow rate is 1 mL / min. Through HPLC separation and purification, it is identified that the radiochemical purity is greater than 99%, and the radiochemical yield is 8%-31%.

[0106] Example 12 Performance of Imidazolopyridone Compounds Binding to σ2 Receptor / TMEM97

[0107] The σ2 receptor / TMEM97 ligand and the corresponding 18 The F-labeled compound was prepared from Example 1-12.

[0108] 1. Radioligand receptor competition binding assay (K i Value determination):

[0109] The in vitro affinity of sigma receptor ligand compounds for sigma receptors was determined using a radioligand receptor competition binding assay.

[0110] The affinity of σ1 receptor was determined using HEK293 cells transfected with human σ1 (Université de Nice Sophia-Antipolis, France) and (+)-[ 3 H]pentazocine (PerkinElmer, 1050 GBq / mmol) was used as the receptor organizer and binding ligand.

[0111] The affinity of σ2 receptor / TMEM97 was determined by using rat liver membrane protein and [ 3 H]DTG (PerkinElmer, 1850 GBq / mmol, in the presence of 100 nM FTC-146) served as the receptor organizer and binding ligand.

[0112] The (+)-[ 3 H]pentazocine and [ 3 H]DTG nonspecific binding. (+)-[ 3 H]pentazocine and [ 3 The dissociation constant K of H]DTG d 33nM and 50nM respectively.

[0113] (1) Rat liver was homogenized, washed with 50 mM Tris-HCl buffer (pH=7.4, room temperature), centrifuged (15000 r / min), and the supernatant was discarded. The liver was washed with buffer and centrifuged again. This process was repeated 5-6 times. The liver was frozen at a ratio of 1 g tissue / 10 mL buffer for later use. The homogenate of human sigma-1 transfected HEK293 cells used to determine the affinity of σ1 receptor was treated in the same manner as above.

[0114] (2) Take 5 mL of frozen membrane protein tissue, thaw and centrifuge, wash twice with buffer, and then add buffer to dilute to 12 mL of solution for use.

[0115] (3) Dissolve the compound in DMSO and prepare a buffer solution at a concentration of 10 -11 M-10 -5 The solution of M is reserved.

[0116] (4) The experiment was divided into a total binding group, a nonspecific binding group, and an experimental group. 100 μL of the corresponding radioligand, 200 μL of tissue fluid, and 700 μL of binding buffer were added to the total binding group. 100 μL of haloperidol was added to the nonspecific binding group, and 200 μL of tissue fluid was replaced with the test compound solution in the experimental group. The total volume of the three groups was 1 mL.

[0117] (5) After vortexing the solution, incubate at room temperature for 60 min, and vacuum filter through glass fiber filter paper (GF / B) pre-treated with 0.3% fresh PEI (90 min, 4°C). Collect membrane proteins and free radioactive ligands with a cell harvester, and place the filter membrane in a counting tube to measure the radioactivity count.

[0118] (6) The experiment was repeated three times, and the concentration of the compound required to reduce the amount of radioligand binding to the receptor by half (IC 50 value), applying the Cheng-Prusoff equation, by IC 50 The inhibition constant (K i value).

[0119]

[0120] In the above formula, [LT] is the concentration of radioligand, Kd K is the equilibrium dissociation constant for the binding of radioligand to receptor, d It can be obtained by Scatchard method, from the above K d and IC 50 The above formula can be used to calculate the K value of the ligand. i The calculation results are shown in Table 1.

[0121] Table 1 Inhibition constants of compounds on σ1 receptor and σ2 receptor / TMEM97

[0122]

[0123] The above competitive binding experiment results show that the compound of Example 7 has high affinity (nanomolar order) and high subtype selectivity for σ2 receptor / TMEM97, and is one of the few reported σ2 receptor / TMEM97 ligands with nanomolar affinity and low lipid solubility for PET imaging. That is, the imidazopyridone compound prepared in Example 7 and the radionuclide prepared in Example 11 18 F-labeled compounds have the potential to be developed into clinically applicable σ2 receptor / TMEM97 tumor imaging agents.

[0124] 2. Example 11 prepared 18 F-labeled imidazopyridone σ2 receptor / TMEM97 compounds [ 18 Physicochemical properties of F]8

[0125] 2.1 Determination of lipid-water partition coefficient

[0126] Shake flask method: prepare equal volumes of PBS buffer (0.05M, pH=7.4) and n-octanol, mix them evenly and place them overnight for use. Take 3.0 mL of PBS solution and 3.0 mL of n-octanol in a centrifuge tube and add the purified HPLC 18 The F-labeled compound of Example 11 (3.0 MBq, 10 μL) was vortexed for 3 minutes and then centrifuged at 4000 rpm for 5 minutes. 100 μL of PBS buffer and 100 μL of n-octanol solution were taken and the radioactivity count was measured using a γ-counter to calculate log D 7.4 Take the above 2.0mL PBS buffer and 2.0mL n-octanol in a new centrifuge tube, add 1.0mL PBS buffer and 1.0mL n-octanol, repeat the above steps twice, take 100μL PBS buffer and 100μL n-octanol solution, use γ-counter to measure the radioactivity count, and calculate logD 7.4 , three parallel experiments were performed, and the calculation formula of logD was:

[0127]

[0128] D = (radiotracer counts in 1 mL of n-octanol) / (radiotracer counts in 1 mL of PBS buffer)

[0129] The above experiment was repeated three times and the 18 log D of F-labeled compound of Example 11 7.4 =1.62±0.03, indicating 18 The F-labeled compound of Example 11 has lower lipid solubility and is expected to effectively reduce nonspecific binding during biodistribution.

[0130] 2.2 In vitro salt stability

[0131] After HPLC separation and purification 18 The F-labeled compound of Example 11 (0.5 MBq, 100 μL) was prepared into a 7% ethanol saline solution (at room temperature), and the percentage of the parent compound in the 7% ethanol saline solution was analyzed by HPLC injection at 30 min, 60 min and 120 min. An analytical chromatographic column (Agela Venusil MP C18 column, 250×4.6 mm, 5 μm) was used, and the mobile phase for HPLC analysis was preferably 50% acetonitrile aqueous solution containing 0.1% triethylamine, with a flow rate of 1 mL / min. After 30 min, 60 min and 120 min, HPLC detection showed that the radiochemical purity of the parent compound in physiological saline was >99%. The results are shown in the attached Figure 1 .

[0132] 3. 18 In vivo biological evaluation of F-labeled compound of Example 11

[0133] 3.1 18 Normal distribution of F-labeled compound of Example 11 in normal ICR mice

[0134] Experimental mice: 25 normal male ICR mice (18-22g, 4-5 weeks old). Inject 0.1 mL of 18The compound of Example 11 labeled with F (296-370 kBq) was injected at 2 min, 15 min, 30 min, 60 min and 120 min, and blood, whole brain, heart, liver, spleen, lung, kidney, pancreas, meat, bone, stomach, small intestine and tail were collected. The organs were weighed (except stomach, small intestine and tail), and the radioactive count (CPM) of each organ was measured by γ-counter. In addition, 10% of the injection volume of three sets of data was taken in parallel together with the residual count of the tail as data correction, and the %ID / organ or %ID / g (radioactive percentage dose per gram of organ) of each organ was calculated. The results are shown in Table 2.

[0135] Table 2 18 Distribution of F-labeled compound of Example 11 in normal ICR mice (% ID / g, mean ± SD, n = 4-5) a

[0136]

[0137]

[0138] a Data are means of%ID / g of tissue±SD, n=4-5.

[0139] b Percentage of injected dose per organ.

[0140] From the experimental results in Table 2, we can see that 18 The initial brain uptake value of the F-labeled Example 11 compound in normal ICR mice was low, reaching 1.94±0.19% ID / g at 2 min, and was cleared over time, with brain uptake of 0.76±0.12% ID / g and 0.45±0.08% ID / g at 60 min and 120 min, respectively. The brain / blood ratio reached a maximum of 3.65±0.65 at 30 min. 18 The F-labeled compound of Example 11 had higher initial uptake values ​​in the heart, lung, and kidney (12.53±1.34% ID / g, 46.94±4.70% ID / g, and 20.44±2.67% ID / g, respectively), and decreased over time. The uptake value in the liver first increased and then decreased over time, and the uptake value in the small intestine increased from low to high, indicating that 18 The F-labeled compound of Example 11 may be metabolized by the liver and small intestine. 18The bone uptake of the F-labeled compound of Example 11 did not increase over time from 2 min to 120 min, indicating that it had no obvious defluorination phenomenon in mice and had good in vivo stability.

[0141] 3.2 18 Inhibitory experiment of F-labeled compound of Example 11 in normal ICR mice

[0142] Experimental mice: 5 normal ICR mice (18-22g, 4-5 weeks old). 0.1mL CM398 solution (5μmol / kg or 10μmol / kg) was injected into the tail vein in advance, and 0.1mL was injected 5 minutes later. 18 F-labeled compound of Example 11 (296-370 kBq), 30 minutes later, blood, whole brain, heart, liver, spleen, lung, kidney, pancreas, meat, bone, stomach, small intestine, tail were collected. The determination method was the same as 3.1, and the inhibition test group and the normal test group were analyzed for significant differences (p value). The results are shown in Table 3.

[0143] Table 3 18 Inhibitory experiment of the compound of Example 11 labeled with F in normal ICR mice (% ID / g, mean ± SD, n = 5) a

[0144]

[0145]

[0146] a Data are expressed as percentage of injected dose per gram,means±SD,n=4-5. b p values ​​for the control vs blocking group at 30min postinjectioncalculated by Student's t test.

[0147] According to the results of the inhibition experiment (Table 3 and Appendix Figure 2 ) shows that CM398 (5 μmol / kg) has an effect on 18The F-labeled compound of Example 11 had a significant inhibitory effect on the organs expressing σ2 receptor / TMEM97 in mice, such as the brain (-73%, p<0.001), heart (-64%, p<0.001), liver (-42%, p=0.001), spleen (-79%, p<0.001), lung (-84%, p<0.001), kidney (-83%, p<0.001), muscle (-50%, p=0.003) and bone (-69%, p=0.001), and the brain / blood ratio inhibition rate reached 87% (p<0.001), and there were significant differences. 18 The F-labeled compound of Example 11 binds to the σ2 receptor / TMEM97 in mice with high specificity. In addition, the uptake inhibition rate of each organ did not increase significantly with the increase of CM398 concentration, indicating that 5 μmol / kg of CM398 is sufficient to block the σ2 receptor / TMEM97 in mice.

[0148] 3.3 18 P-gp substrate assay of the compound of Example 11 labeled with F

[0149] P-gp inhibitor Tariquidar (1 mg / mL, 10% DMSO, 20% 1,2-propylene glycol, 30% PEG400, 40% saline) was prepared for use. Normal ICR male mice (18-22 g, 4-5 weeks) were injected with Tariquidar (5 mg / kg) through the tail vein 30 minutes before administration. 18 F-labeled Example 11 compound (296-370 kBq, 0.1 mL, physiological saline solution containing about 7% ethanol). After 2 minutes, blood, whole brain and tail were collected and weighed separately (except tail), and the radioactive counts (CPM) were determined using a γ-counter. Another 10% injection volume of three parallel data was taken together with the residual counts in the tail as data correction, and the %ID / g or inhibition percentage of blood and whole brain was calculated. The experimental results are shown in the attached Figure 3 .

[0150] According to the experimental results (Appendix Figure 3 ) It can be seen that injection 18 2 minutes after the administration of the F-labeled compound of Example 11, the radioactive uptake in the brain and blood of normal mice was 1.94±0.19% ID / g and 1.58±0.27% ID / g, respectively, and the brain / blood ratio was 1.25±0.17. The radioactive uptake in the brain and blood of the mice in the experimental group injected with Tariquidar in advance was 7.51±0.83% ID / g (p<0.001) and 2.03±0.11% ID / g (p=0.09), respectively, and the brain / blood ratio was 3.69±0.37 (p<0.001). 18The mouse brain uptake and brain / blood ratio of the F-labeled compound of Example 11 increased by 287% and 195%, respectively, indicating that 18 The F-labeled compound of Example 11 is a P-gp substrate.

[0151] 3.4 18 Metabolism and stability evaluation of F-labeled compound of Example 11 in normal ICR mice

[0152] Nude mice bearing CT26 tumors (16-20 g, n = 3) were injected into the tail vein 18 The animals were anesthetized and killed 30 minutes after the addition of the compound of Example 11 labeled with F (0.8-1.0 mCi, 0.1 mL). The blood, whole brain, tumor and liver were collected in centrifuge tubes. The blood stains remaining on the surface of the organs were washed with physiological saline. Acetonitrile (4°C, 0.5 mL) was added and the tissue was ground with a homogenizer. The radioactive substances were extracted with acetonitrile. The mixture was vortexed and centrifuged. The supernatant was then taken to a new centrifuge tube and acetonitrile was added to precipitate the protein. The mixture was centrifuged and acetonitrile was added repeatedly until no new precipitation was generated. The solution was filtered with a 0.22 μm organic filter membrane and then used. The obtained solution was analyzed by HPLC system. Analysis conditions: Analytical column Agela Venusil MP C18, 5 μm, 250×4.6 mm, mobile phase was 50% acetonitrile and 50% water (0.1% TEA), and the flow rate was 1 mL / min. The experimental results are shown in Table 4 and Appendix Figure 4 .

[0153] Table 4 Injection 18 Percentage of radioactive metabolites and parent tracer in mouse plasma, brain, liver and tumor after 30 min of F-labeled Example 11 compound (n=3) a

[0154]

[0155] a Data are expressed as percentage of total radioactivity,means±SD.

[0156] According to the results of metabolic experiments (Table 4 and Appendix Figure 4 ) It can be seen that 18 The retention time of the F-labeled compound of Example 11 in HPLC was 12.49 min. In the brain and tumors, 18 The radioactive signal content of the parent compound of Example 11 labeled with F was greater than 90%, and the radioactive signal content of the parent compound in the tumor was as high as 98%. Only a small amount of hydrophilic radioactive metabolites were produced at 2.8min and 3.5min. In the blood and liver, 18The radioactive signal contents of the parent compound of Example 11 labeled with F were 41.79±4.07% and 67.48±0.52%, respectively. 18 The F-labeled compound of Example 11 has good stability in mouse brain and tumors, and the results are consistent with the results of the biodistribution inhibition experiment in normal mice and the inhibition experiment in nude mice bearing CT26 tumors.

[0157] 3.5 18 Micro-PET / CT imaging of nude mice bearing CT26 tumors by F-labeled compound of Example 11

[0158] Nude mice bearing CT26 tumors (18-20 g, n=4-7) were injected with the drug via tail vein. 18 F-labeled Example 11 compound (6.5-10 MBq, 0.1 mL). After administration for 30 minutes and 90 minutes respectively, the subjects were anesthetized with 1.5-2.5% isoflurane oxygen flow (1-2 L / min) and weighed, then fixed on the data acquisition bed and positioned in the center of the parallel scanner, and the flow was adjusted to 0.8-1.0 L / min (containing 1.5-2.0% isoflurane). Under the set PET data acquisition program, data were continuously collected for 10 minutes and CT scans were performed for 10 minutes.

[0159] Inhibition experiment group: CM398 inhibition experiment verifies the tracer in the tumor 18 The specificity of the F-labeled compound of Example 11 for σ2 receptor / TMEM97 was determined by using the inhibitor CM398 (5 umol / kg, 0.1 mL) and 18 The F-labeled compound of Example 11 was co-injected, and PET / CT data of the static phase of 30min and 90min were collected. After the instrument completed data collection, the weight (g), initial activity of radioactivity, residual activity (GBq) and specific acquisition time of the mouse were input, and the quantitative data were corrected and reconstructed, with CT scanning as the basis for positioning. The reconstructed data was image and data processed by PMOD to calculate the radioactivity uptake SUV in the mouse tumor and lung max The results of the CT26 tumor imaging experiment are shown in Table 5 and Appendix Figure 5 .

[0160] Table 5 18 PET imaging results of the F-labeled compound of Example 11 in CT26 tumor mice a

[0161]

[0162] a Data are expressed as SUV max,means±SD.

[0163] b n=7

[0164] c n=4

[0165] b p values ​​for the control vs blocking group was calculated byStudent's t test(independent,two-tailed).

[0166] Quantitative analysis of PET imaging experiments by PMOD (Table 5 and Appendix Figure 5 ) It can be seen that injection 18 30 min after the administration of the compound of Example 11 labeled with F, there was obvious radioactivity accumulation in the tumor area. Radioactivity uptake SUV of the tumor in the normal group max was 1.05±0.24, the lung uptake value was lower, and SUV max The radioactivity uptake SUV of tumors in the CM398 inhibition group was 0.41±0.13, and the tumor / lung ratio was 2.39±0.97. max 0.37±0.10, lung SUV max The tumor / lung ratio was 0.20±0.07, the tumor / lung ratio was 2.01±0.71, and the tumor tracer uptake inhibition rate was 65% (p<0.001). 18 SUV of the tumor in the normal group after 90 min of F-labeling with the compound of Example 11 max 1.13±0.22, lung SUV max The radioactivity uptake SUV of tumors in the CM398 inhibition group was 0.28±0.07, and the tumor / lung ratio was 3.71±0.72. max Lung SUV was 0.25±0.08 max The tumor / lung ratio was 0.13±0.04, the tumor / lung ratio was 1.94±0.29, and the tumor tracer uptake inhibition rate was 78% (p<0.001). The results of PET imaging and inhibition experiments are shown in Table 5 and Appendix Figure 5 The experimental results show that 8 The F-labeled compound of Example 11 has a highly specific binding to the σ2 receptor / TMEM97, with a higher tumor uptake value and a lower lung uptake value. Moreover, as time goes by, the tumor uptake value increases while the lung uptake value decreases, making the PET imaging effect clearer, as shown in FIG. Figure 5 shown.

[0167] 3.6 18 PET / CT imaging of the F-labeled compound of Example 11 in CT26 lung compression model mice

[0168] Experimental control group: CT26 lung compression model mice (17.3 g), fasted for 12 hours in advance, injected with [ 18 F]FDG (7.2MBq, 0.1mL) was administered 60min after which the subjects were anesthetized with 1.5-2.5% isoflurane and oxygen flow (1-2L / min) and then fixed on the data acquisition bed and positioned in the center of the parallel scanner to adjust the flow to 0.8-1.0L / min (containing 1.5-2.0% isoflurane). Under the set PET data acquisition program, data were continuously acquired for 10min and CT scans were performed for 10min.

[0169] Experimental group: mice were fed with normal diet and injected with drugs via tail vein 18 The compound of Example 11 labeled with F (9.6MBq, 0.1mL) was then anesthetized with 1.5-2.5% isoflurane oxygen flow (1-2L / min) and weighed, then fixed on the bed for data acquisition and positioned at the center of the parallel scanner, the air flow was adjusted to 0.8-1.0L / min (containing 1.5-2.0% isoflurane), and PET images were collected for 0-60min according to the program settings. After the PET information was collected, CT images were collected for 10min. After the instrument completed data collection, the weight (g), initial activity of radioactivity, residual activity (GBq) and specific acquisition time of the mouse were input, the quantitative data were corrected and reconstructed, and the CT scan was used as the basis for positioning. 18 The PET images of the F-labeled compound of Example 11 were divided into 10min×6 frames. Based on the CT images, the region of interest (ROI) was drawn and the PET images were integrated to calculate the standardized uptake value (SUV) of the ROI and construct the time-activity curve (TACs). The reconstructed data of the experimental control group were processed by PMOD to calculate the radioactive uptake SUV in the mouse tumor and lung. max The experimental results show that [ 18 The uptake value of F]FDG in the mouse heart was very high, but the uptake value in the tumor was relatively low, and the lung tumor imaging was not obvious. 18 Compared with F]FDG, 18 The F-labeled compound of Example 11 had a higher uptake value in CT26 tumors, but a lower uptake value in the heart, with a higher tumor / lung ratio and tumor / heart ratio, and clear tumor imaging. The imaging experiment results are shown in the attached Figure 6 .

[0170] 3.7 18 In vitro autoradiography and macroscopic oil red staining of atherosclerotic mouse aorta with the F-labeled compound of Example 11

[0171] ApoE fed for 20 weeks- / - Mice (n=1) and wild-type mice (n=1) were injected via tail vein 18 F-labeled Example 11 compound (1.11 MBq, 0.1 mL). All mice were anesthetized and killed 2 h after injection, and the heart and the entire aorta were removed under a dissecting microscope, and the adipose tissue around the aorta was removed. The aorta was rinsed with physiological saline, the surface droplets were blotted off, and exposed to a storage phosphor screen (PerkinElmer, USA) for 10 min. Subsequently, the radioactive autoradiographic image was scanned using a storage phosphor screen imaging system (Cyclone Plus, PerkinElmer, USA).

[0172] After the radioactive autoradiography is completed, the aorta is fixed in paraformaldehyde for more than 24 hours and then removed. The fat around the blood vessels is removed and the blood vessels are cut open longitudinally. The blood vessels are first immersed in 60% isopropanol for 3 seconds, then immersed in Oil Red O dye solution at 37°C and stained in the dark for 60 minutes. The blood vessels are then taken out and immersed in 60% isopropanol for differentiation until the fat plaques in the lumen are orange-red or bright red, and other parts are almost colorless, and then washed with distilled water to terminate the differentiation. The aorta is taken out, excess water is absorbed, and then placed on a black background board with a ruler for photography.

[0173] The images were analyzed using Image J. The quantitative results were expressed as the percentage of lipid accumulation lesion area to the total aorta area. Under the dissecting microscope, it can be seen that there are macroscopic atherosclerotic plaques in the aortic arch of atherosclerosis model mice. The results of macroscopic Oil Red O staining show that the lipid droplets in this area are bright red, indicating that atherosclerotic plaques have indeed formed in this area. In contrast, the aorta of wild-type mice is almost colorless in the macroscopic Oil Red O staining. The lipid content (56.1%) and the ratio of the positive area of ​​radioactive concentration (39.7%) are similar. More importantly, the radioactive counts in the bright red areas of the aorta of plaque model mice are significantly higher than those in the colorless areas in Oil Red O staining. The radioactive autoradiography images were analyzed using AIDA2.31 software. The red areas of the Oil Red O staining images were used as lesions, and the colorless areas of the Oil Red O staining images were used as background. The regions of interest were manually outlined in the radioactive autoradiography images, and the radioactive counts of the regions of interest were automatically calculated by the software. The target / bench ratio was calculated to be 2.42, indicating that the tracer 18 The F-labeled compound of Example 11 accumulated in the atherosclerotic plaques in the aorta, and the tracer has the potential to be used for atherosclerotic plaque imaging. Figure 7 .

[0174] 3.8 18 Micro-PET / CT imaging of atherosclerotic mice with the F-labeled compound of Example 11

[0175] After 20 weeks of feeding, ApoE- / - mice (n=4) or wild-type mice (n=1) were injected with tracer into the tail vein. 18 F-labeled compound of Example 11 (7.40-9.25 MBq, 0.1 mL) was added, and in vivo static micro-PET / CT imaging was performed 60 min later. The PET scanning time, anesthesia method, CT scanning and image reconstruction method were the same as above. In order to eliminate the interference of the thymus on the image of the aortic arch, some mice (n=1) were immediately killed after the in vivo imaging, and the thymus was removed by thoracotomy, followed by micro-PET / CT static imaging. The imaging method was the same as above.

[0176] The imaging results showed that 18 The uptake value of the F-labeled Example 11 compound in the aortic arch region of the plaque model mice (0.33±0.05) was significantly higher than that of the wild-type mice (0.16). The imaging results showed that the thymus was located near the aortic arch and had a high uptake, which would interfere with the drawing of the region of interest (VOI) in the aortic arch region. Therefore, in this study, the mice were anesthetized and killed immediately after the 60-minute static imaging, and the thymus was removed by thoracotomy. The whole-body imaging was then performed to eliminate the interference of the thymus. The results are shown in the attached Figure 8 After the thymus was removed, there was still obvious radioactive uptake in the aortic arch of the plaque model mice, indicating that 18 The F-labeled compound of Example 11 accumulated at the site of atherosclerotic plaques.

[0177] The above experimental results show that 18 The F-labeled imidazopyridone σ2 receptor / TMEM97 ligand has high affinity, high subtype selectivity and high specificity for σ2 receptor / TMEM97. 18 F labeling has a high radiochemical yield and radiochemical purity, and has excellent in vitro and in vivo biological properties. In PET imaging of nude mice bearing CT26 tumors, 18 F-labeled imidazopyridone σ2 receptor / TMEM97 ligand can clearly perform PET imaging of CT26 tumors, with high specific tumor uptake, low lung uptake, and a high tumor / lung ratio. As time goes by, the tumor uptake value increases, while the lung uptake value decreases, making the PET imaging effect clearer. In PET imaging of CT26 lung compression model mice, 18 The F-labeled compound of Example 11 can clearly image lung tumors without interference from the heart and lung background, and [ 18 Compared with F]FDG, it has a greater advantage in imaging tumors around the lungs and heart.

[0178] therefore, 18F-labeled imidazopyridone σ2 receptor / TMEM97 ligand is an excellent specific CT26 tumor imaging agent, which is expected to be used for imaging studies of colorectal cancer lung metastasis and other tumors around the lungs and heart, providing a visualization tool for personalized clinical treatment of cancer in the future. 18 F-labeled imidazopyridone σ2 receptor / TMEM97 ligand has the potential to image atherosclerotic plaques. σ2 receptor / TMEM97 is a potential marker for atherosclerotic plaques. PET imaging targeting σ2 receptor / TMEM97 can be used to monitor the formation and progression of plaques and to evaluate the effectiveness of plaque treatment.

[0179] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.

Claims

1. A compound that binds to σ2 receptor / TMEM97, characterized in that It has the structure shown in general formula (I): Where: R is F or 18 F.

2. The method for preparing the compound according to claim 1, characterized in that: When R in the general formula (I) is F or 18 When F, the corresponding compound is prepared by the following synthetic route: The preparation steps corresponding to the above synthetic route are as follows: (a) In tetrahydrofuran solvent, compound 1 (2-amino-3-nitro-6-methoxypyridine) reacts with di-tert-butyl dicarbonate under the action of 4-dimethylaminopyridine, followed by the addition of potassium carbonate and methanol to obtain compound 2; the reaction temperature is 55-65°C; (b) In methanol solvent, compound 2 reacts with 10% palladium on carbon under a hydrogen atmosphere to obtain compound 3; the reaction temperature is 50°C; (c) In tetrahydrofuran solvent, compound 3 reacts with N,N'-carbonyldiimidazole in the presence of triethylamine to obtain compound 4; (d) In a solvent of N,N-dimethylformamide, compound 4 reacts with 1,4-dibromobutane in the presence of potassium carbonate and tetrabutylammonium iodide to obtain compound 5; the reaction temperature is 60°C; (e) In acetonitrile as a solvent, compound 5 reacts with 5,6-dimethoxyisoindoline in the presence of potassium carbonate and triethylamine to obtain compound 6; (f) Compound 6 reacts with trifluoroacetic acid in a solvent of dichloromethane at room temperature to obtain compound 7; (g) In a solvent of N,N-dimethylformamide, compound 7 reacts with 1-bromo-2-fluoroethane in the presence of potassium carbonate and tetrabutylammonium iodide to obtain compound 8; the reaction temperature is 65° C.; (h) In a solvent of N,N-dimethylformamide, compound 7 reacts with (2-bromoethoxy)-tert-butyldimethylsilane in the presence of potassium carbonate and tetrabutylammonium iodide to obtain compound 9; the reaction temperature is 60° C.; (i) Compound 9 reacts with 4 mol / L methanolic hydrochloric acid at room temperature in methanol solvent to obtain compound 10; (j) In a solvent of dichloromethane, compound 10 reacts with p-toluenesulfonyl chloride in the presence of triethylamine and 4-dimethylaminopyridine at room temperature to obtain compound 11; p-toluenesulfonyl chloride is added at 0°C; (k) Under sealed conditions, compound 11 and 4,7,13,16,21,24-hexaoxo-1,10-diazabicyclo[8.8.8]hexacosane (K 2.2.2 ) reacts under the action of potassium carbonate to obtain 18 F-labeled imidazopyridone σ2 receptor / TMEM97 compounds [ 18 F]8.

3. A ligand targeting σ2 receptor / TMEM97, characterized in that: Contains the compound represented by the general formula (I) according to claim 1.

4. A molecular probe for binding to σ2 receptor / TMEM97, characterized in that: Containing the general formula (I) of claim 1 wherein R is 18 F is the corresponding compound.

5. A tumor imaging agent targeting σ2 receptor / TMEM97, characterized in that: Containing the general formula (I) wherein R is 18 F is the corresponding compound.

6. Use of the molecular probe for binding to σ2 receptor / TMEM97 according to claim 5 in positron emission tomography imaging agents.

7. Use of the molecular probe for binding σ2 receptor / TMEM97 as claimed in claim 5 in the preparation of products for diagnosis, staging or efficacy evaluation of cancer patients.

8. Use of the tumor imaging agent targeting σ2 receptor / TMEM97 according to claim 6 in positron emission tomography imaging agents.

9. Use of the tumor imaging agent targeting σ2 receptor / TMEM97 according to claim 6 in the preparation of products for diagnosis, staging or efficacy evaluation of cancer patients.

10. Use of the imaging agent targeting σ2 receptor / TMEM97 according to claim 6 in the preparation of a product for diagnosis, staging or efficacy evaluation of patients with atherosclerosis.

Citation Information

Patent Citations

  • Tetrahydroisoquinoline and isoindoline compounds combined with sigma-2 receptor as well as preparation method and application of tetrahydroisoquinoline and isoindoline compounds

    CN115286616A

  • Highly selective sigma receptor ligands

    WO2009026227A2